Colorectal cancer (CRC) is one of the most common cancers globally as well as in Japan and has shown a pattern of increasing incidence and mortality rates. Therefore, guidelines for CRC are considered to be crucial for establishing standard medical treatment not only in Japan but also around the world. In this article, we explain
| Guidelines of the NCCN
In terms of the diagnosis, surgery and treatment by each disease state, comprehensive contents are mainly described as a flow chart, followed by about 60 pages of discussion based on the latest clinical trials and evidence. Regarding the recommendation level, these guidelines include four categories established based on available evidence and the consensus: category 1, 2A, 2B and 3 (if not specified, the recommendation level of an item category is 2A). These guidelines are characterized by frequent revision, and the latest clinical evidence is therefore likely to be reflected promptly.
| Guidelines of the ESMO
These guidelines are prepared by the ESMO, and descriptions concerning CRC are divided into four categories: (i) early colon cancer; 5 (ii) rectal cancer; 6, 7 (iii) metastatic colorectal cancer; 8 and (iv) familial risk colorectal cancer. 9 Revisions are made once every 2-3 years. In contrast to the NCCN guidelines, ESMO guidelines mainly contain a review-style description format, and the contents based on the latest evidence are briefly summarized. As there is no detailed flow chart or algorithm for subdivision, a comparison with other guidelines such as those of the JSCCR or NCCN suggests that practical usefulness (eg selecting a specific chemotherapy regimen) might be inferior.
An adapted version of the "Infectious Disease Society of America-United States Public Health Service Grading system" is used to define the level of evidence (I-V) and strength of each recommendation (A-E) in these guidelines.
3 | COMPARISON OF THE TREATME NT
METHOD S FOR CRC IN JAPAN, THE USA AND EUR OPE
Here, we compare the treatment methods for CRC described in each set of guidelines, particularly with regard to: (i) local treatment, including endoscopic treatment and transanal excision for lower rectal cancer; (ii) surgical treatment with lymph node dissection, including management of lower rectal cancer with lateral lymph node metastasis and laparoscopic surgery; and (iii) chemotherapy.
| Local treatment
For Tis (M) or some T1 (shallow submucosal invasion) tumors without any findings of lymph node metastasis, local treatment such as endoscopic treatment or transanal excision for lower rectal cancer was feasible under each set of guidelines.
In the JSCCR guidelines, endoscopic treatment through endoscopic mucosal resection (EMR) or endoscopic submucosal dissection resection margin. In the JSCCR guidelines, in addition to these factors, the pathological finding of deep submucosal invasion (>1000 lm) and budding grade 2/3 are considered to be an indication for additional surgical procedures with lymph node dissection, as the risk of lymph node metastasis is reported to be higher in these lesions than in those without such risk factors. 10 For adequate treatment of T1 CRC, accurate endoscopic evaluation of the invasion depth based on the morphological findings by magnified endoscopy or Kudo's pit pattern classification 11 is considered to be important.
In the NCCN guidelines, transanal excision is described as appropriate only for select T1, N0 cancers (<3 cm in diameter), well to moderately differentiated tumors located within 8 cm of the anal verge and limited to less than 30% of the rectal circumference. In the JSCCR guidelines, the adapted tumor location for transanal excision is described as rectal lesions of the second Houston valve, and the need for additional resection with lymph node dissection is determined by a histopathological assessment of the surgical specimens (excisional biopsy). Indication for additional resection is the same as with endoscopic treatment, as mentioned earlier.
| Surgical treatment
Basic treatment strategy for localized CRC without distant metastasis is surgery with lymph node dissection, especially for lesions with invasion deeper than the submucosal layer. Management of lateral lymph node metastasis with lateral lymph node dissection (LLND) or preoperative chemoradiation therapy (CRT) is a major topic in each set of guidelines. In addition, laparoscopic surgery is an important newly developed treatment strategy for CRC.
| Management of lateral lymph node metastasis
In the JSCCR guidelines, tumor staging is defined by the Japanese classification of CRC. Under this classification system, lymph node metastasis around iliac and obturator artery is defined as lateral lymph node metastasis. Such metastases are considered to be regional lymph node metastasis rather than distant metastasis (Table 1) , although the survival rate with lateral lymph node metastasis is reported to be poor. 12 Therefore, in the JSCCR guidelines, total mesorectal excision (TME) (or tumor-specific mesorectal excision [TSME]) with LLND for T3-4 lower rectal cancers is recommended, and effective reduction of local recurrence and improved survival rate are shown. 13 Although the revised American Joint Committee on Cancer (AJCC) staging system also defines internal iliac lymph nodes as regional lymph nodes of rectal cancer, 14 preoperative CRT followed by TME without LLND is recommended for advanced rectal cancer in the NCCN and ESMO guidelines. Preoperative CRT is reported to reduce the risk of local recurrence but not to improve the survival rate. 15 Although the effectiveness of preoperative CRT is described as "not established" in the JSCCR guidelines, a randomized control trial (RCT)
from Japan showed no difference in either the overall or disease-free survival between the groups of surgery with and without LLND after CRT; however, urinary and sexual function were significantly better in the group without LLND than in the group with it. 16 Efficacy and safety of preoperative CRT warrant future further assessment.
| Laparoscopic surgery
Nowadays, laparoscopic surgery for CRC is carried out at many institutions around the world, and the efficacy and safety of the 
| Chemotherapy
Chemotherapy for CRC consists of adjuvant chemotherapy to prevent postoperative recurrence and systemic chemotherapy to treat unresectable progressive CRC. Approved anticancer drugs for CRC in Japan are shown in Table 2 . RCT from Japan also showed that tegafur-gimeracil-oteracil potassium (S-1) as adjuvant chemotherapy for patients with stage III colon cancer is not inferior to UFT+LV. 31 Given these results, in the JSCCR guidelines, oral UFT+LV, Cape and S-1 are recommended as adjuvant chemotherapy in addition to OX combined regimens, such as FOLFOX and CapeOX, for patients with stage III or high-risk CRC (Table 3) .
| Adjuvant chemotherapy
Regarding timing and duration, in the JSCCR guidelines, it is recommended to start adjuvant chemotherapy within 4-8 weeks after surgery and continue for 6 months. In the ESMO guidelines, induction timing of adjuvant chemotherapy is described as "as early as antibodies and is the preferred option for KRAS mutant tumors.
